Intermittent immunotherapy in patients with metastatic kidney cancer
The combination of ipilimumab/nivolumab is approved for patients as a [...]
Patient perspectives on reduced treatment schedules for immunotherapy
Immunotherapy has transformed the treatment of many cancers, including kidney [...]
The Big Cancer52 Conversation
The third Big Cancer52 Conversation took place on 19 June [...]
Belzutifan compared to everolimus for advanced kidney cancer
People with kidney cancer have been shown to have changes (mutations) in [...]
Exercise may improve quality of life for kidney cancer patients
A recent study presented by the Australia and New Zealand [...]
Cancer waiting times: latest updates
Over the past few years, there has been extreme pressure [...]
WECAN Academy 2024
Mid July, one of the Action Kidney Cancer team, Steve [...]
FDA grant fast track status to CAR T cell therapy for kidney cancer
The Food and Drug Administration (FDA) in America has granted [...]
Perioperative nivolumab in intermediate/high risk kidney cancer patients
The standard of care for patients with intermediate/high risk kidney [...]
Why the next UK Government must set out a new strategy for cancer
With an election weeks away, political parties have the opportunity [...]
